Safty and Efficacy of MCI Network Guided TMS for Early Alzheimer's Disease: A Randomized, Double-… (NCT07138677) | Clinical Trial Compass
CompletedNot Applicable
Safty and Efficacy of MCI Network Guided TMS for Early Alzheimer's Disease: A Randomized, Double-blind Trial
China40 participantsStarted 2025-07-20
Plain-language summary
Estimate the safty and efficacy of personalized network neuronavigated transcranial magnetic stimulations in early Alzheimer's disease patients
Who can participate
Age range
45 Years – 85 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Subject diagnosed as either mild cognitive impairment due to AD or mild AD dementia based on National Institute on Aging-Alzheimer's Association criteria.
. MMSE score 18-28.
. CDR score 0.5-1.
. On stable treatment with IAChE or memantine for at least 6 months.
. Literate in Han Chinese.
Exclusion criteria
. Recevied rTMS treatment in the past 3 months.
. Depression or other psychiatric disorders.
. History of head injury, stroke, epilepsy or other neurologic disease.
. Organic brain defects on T1 or T2 images.
. History of unexplained loss of consciousness.
. Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, or any implanted medical device that is incompatible with MRI.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial used brain network-guided TMS targeting people with early Alzheimer's disease — does my current stage of cognitive decline match the kind of patient who was enrolled in this study?
2Since the trial has already completed, has the results data been published yet, and can you walk me through what the ADAS-Cog scores showed about whether the TMS treatment actually slowed cognitive decline?
3This study is listed as Phase NA, which suggests it may not follow the standard drug-trial phases — what does that mean for how confident we can be in the safety and effectiveness findings compared to a Phase 2 or Phase 3 trial?
4The trial used individualized navigation to guide the TMS to each person's specific brain network — how does that differ from standard TMS approaches, and would that personalized targeting be available outside of a research setting if the results look promising?
5Given that this trial is now completed, would you recommend I consider a similar ongoing study, or is there a standard-of-care treatment I should try first before looking at TMS options?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.